<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714504</url>
  </required_header>
  <id_info>
    <org_study_id>Fusarium prophylaxis</org_study_id>
    <nct_id>NCT02714504</nct_id>
  </id_info>
  <brief_title>Anti-mold Azole in the Prophylaxis for Invasive Fusariosis</brief_title>
  <acronym>Fusarproph</acronym>
  <official_title>Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients admitted for autologous or allogeneic hematopoietic cell transplantation,
      induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid
      leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with
      dermatologic examination. In the presence of any skin lesion in the extremities, direct exam
      and fungal culture will be performed. If these exams indicate the presence of Fusarium
      species, patients will receive anti-mold azole prophylaxis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted for autologous or allogeneic hematopoietic cell transplantation,
      induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid
      leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened on
      admission. Patients may be included more than once, provided that a new treatment is
      administered and &gt;30 days elapses from one to other admission (episode).

      Screening will consist of a thorough physical examination in the extremities. In case of a
      skin lesion, direct exam and fungal culture will be performed. Nail samples will be obtained
      by scrapping the nails with a curette, and samples from interdigital areas will be obtained
      using swabs.

      In a first phase no intervention will be performed. In a second phase, if direct exam and /or
      culture indicate the presence of Fusarium spp., primary antifungal therapy with an anti-mold
      azole (voriconazole (200 mg BID) or posaconazole (200 mg TID) will be started.

      Patients will be followed until discharge. The primary endpoint is invasive fusariosis,
      comparing the observational period with the intervention period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery</measure>
    <time_frame>Until neutrophil recovery, for an average of 4 weeks</time_frame>
    <description>Proportion of patients who develop invasive fusariosis until neutrophil recovery, for an average of 4 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Fusariosis</condition>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-mold prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole or posaconazole</intervention_name>
    <description>Azole with activity against molds</description>
    <arm_group_label>Anti-mold prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission for autologous or allogeneic hematopoietic cell transplantation,
             induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute
             lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia

        Exclusion Criteria:

          -  prior documentation of invasive fusariosis or allergy to azoles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2018</results_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Marcio Nucci</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
    <mesh_term>Fusariosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Observational</title>
          <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
        </group>
        <group group_id="P2">
          <title>Anti-mold Prophylaxis</title>
          <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
Voriconazole or posaconazole: Azole with activity against molds</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observational</title>
          <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
        </group>
        <group group_id="B2">
          <title>Anti-mold Prophylaxis</title>
          <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
Voriconazole or posaconazole: Azole with activity against molds</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="14" upper_limit="66"/>
                    <measurement group_id="B2" value="50" lower_limit="13" upper_limit="72"/>
                    <measurement group_id="B3" value="48" lower_limit="13" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery</title>
        <description>Proportion of patients who develop invasive fusariosis until neutrophil recovery, for an average of 4 weeks</description>
        <time_frame>Until neutrophil recovery, for an average of 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
          </group>
          <group group_id="O2">
            <title>Anti-mold Prophylaxis</title>
            <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
Voriconazole or posaconazole: Azole with activity against molds</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery</title>
          <description>Proportion of patients who develop invasive fusariosis until neutrophil recovery, for an average of 4 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Observational</title>
          <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
        </group>
        <group group_id="E2">
          <title>Anti-mold Prophylaxis</title>
          <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
Voriconazole or posaconazole: Azole with activity against molds</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Marcio Nucci</name_or_title>
      <organization>Univ Fed Rio de Janeiro</organization>
      <phone>552139382463</phone>
      <email>mnucci@hucff.ufrj.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

